Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
H L Hu
Observed names:
Hailong Hu,
Houjia Hu
Institutions:
Second Hospital of Tianjin Medical University,
State Key Laboratory of Experimental Hematology,
Tianjin Medical University
Observed institutions:
Second Hospital of Tianjin Medical University,
State Key Laboratory of Experimental Hematology,
Tianjin Medical University
ORCID:
0009-0002-8635-5939
Observed ORCID:
0009-0002-8635-5939
OpenAlex ID:
A5133808659
BACH2 controls ILC3 function via PPARγ-dependent mitochondrial metabolism
2026
·
Jianye Wang
, Ying Wang
, et al.
·
The Journal of Experimental Medicine
·
2
Urinary tumor DNA–guided de-escalation of systemic immunotherapy in extensive very high risk non–muscle-invasive bladder cancer.
2026
·
Yunkai Qie
, Zihan Xue
, et al.
·
Journal of Clinical Oncology
·
1
Radical cystectomy vs bladder-sparing therapy in very high-risk non–muscle-invasive bladder cancer: Real-world 5-year outcomes and immune checkpoint inhibitor–based substrategy analysis.
2026
·
Jiazeng Zhao
, Yunkai Qie
, et al.
·
Journal of Clinical Oncology
PDF
TRUCE-11: An open-label, single-arm, multicenter phase II study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma.
2026
·
Zhouliang Wu
, Yunkai Qie
, et al.
·
Journal of Clinical Oncology
Cost-effectiveness analysis in the era of systemic immunotherapy for BCG-naive high-risk non–muscle-invasive bladder cancer in the United States, the United Kingdom, and China.
2026
·
Zihan Xue
, Yunkai Qie
, et al.
·
Journal of Clinical Oncology
Long-term survival update of TRUCE-01: A phase 2 study of preoperative tislelizumab combined with low-dose nab-paclitaxel for muscle-invasive bladder cancer (MIBC).
2026
·
Zhouliang Wu
, Yunkai Qie
, et al.
·
Journal of Clinical Oncology
Exploration of biomarkers for TRUCE-01: Development of a urine-based efficacy prediction model.
2026
·
Yuda Lin
, Chong Shen
, et al.
·
Journal of Clinical Oncology
Updated efficacy and safety of SHR-1501, an IL-15RαFc superagonist, with or without Bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.
2026
·
Zhisong He
, Yuke Chen
, et al.
·
Journal of Clinical Oncology
Influence of low-coverage whole-genome sequencing–based urinary tumor fraction and chromosomal instability on recurrence risk stratification in systemic immunotherapy-treated non–muscle–invasive bladder cancer.
2026
·
Yunkai Qie
, Zihan Xue
, et al.
·
Journal of Clinical Oncology
PDF
[Efficacy and safety of transvaginal assisted total intracavitary orthotopic neobladder surgery for female urothelial carcinoma of the bladder].
2026
·
S Liang
, Y K Qie
, et al.
·
PubMed
Show more works
View as search
Works count:
10
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type